Several renowned fund managers have recently revealed their latest investment actions as fund companies disclose their updated holdings. Notably, Zheng Lei, managing Hui Tian Fu Innovation Medicine, has increased his stake in Guobang Pharmaceutical. Meanwhile, Yao Zhipeng, who oversees Jia Shi New Energy Materials, has bolstered his investment in Chuanheng Co., and Gao Nan, managing Yongying Ruixin, has increased his holdings in Tianrun Industry. These three fund managers have made strategic moves this year, focusing on the pharmaceutical, chemical, and new energy sectors.
Zheng Lei Increases Stake in Guobang Pharmaceutical
According to a notice from Guobang Pharmaceutical on March 15, as of March 10, Zheng Lei‘s Hui Tian Fu Innovation Medicine held approximately 3.2557 million shares, representing 0.58% of the company’s total share capital. Guobang Pharmaceutical is a global player in the pharmaceutical manufacturing industry, specializing in the research, production, and sale of pharmaceutical and animal health products. This includes a range of pharmaceutical raw materials, key intermediates, and formulations, as well as animal health products like raw materials and additives.
As of the end of 2024, several public funds, including Dacheng Fund, Nanfang Fund, Xinda Australia Fund, Penghua Fund, and Bosera Fund, are known to hold shares in Guobang Pharmaceutical. Kaiyuan Securities Research believes that the pharmaceutical raw materials sector is experiencing steady growth, and the animal health products segment is expected to contribute significantly to performance. The company is focused on its core business of pharmaceutical raw materials and intermediates while strategically expanding into the animal health market, which may lead to enhanced core product strength over time.
Specifically, due to stable prices of raw materials such as thiocyanate red, the prices of macrolide raw materials have remained stable, and the demand growth has driven a rapid increase in sales for these products. Furthermore, the prices of intermediates like sodium borohydride have stabilized at low levels, and the company’s significant market share is expected to contribute to performance fluctuations. The demand for animal health raw materials is recovering, and it is anticipated that this sector will yield substantial performance elasticity in the coming years. Kaiyuan Securities Research holds a positive outlook on the company’s long-term development.
Yao Zhipeng Increases Stake in Chuanheng Co.
On March 13, Chuanheng Co. announced that Yao Zhipeng‘s Jia Shi New Energy Materials has increased its holdings in the company. As of March 11, the fund held approximately 5.58 million shares, which accounts for 1.04% of Chuanheng’s total shares. Chuanheng is a leading enterprise in the phosphoric chemical sector, having developed various technologies for the industrial production of phosphate products, including monocalcium phosphate, dihydrogen phosphate, and iron phosphate.
Data indicates that by the end of 2024, multiple public funds, such as Fuguo Fund, Nanfang Fund, Great Wall Fund, Huaxia Fund, and Jia Shi Fund, also hold shares in Chuanheng. Zhejiang Merchants Securities Research highlights that Chuanheng possesses substantial phosphate resources, with its subsidiary Fulin Mining holding mining rights for three phosphate mines with a total reserve of 170 million tons. Additionally, a stake in Tianyi Mining holds resources of 370 million tons. The company boasts an existing phosphate production capacity of 3 million tons per year, with additional capacities anticipated in the future.
Gao Nan Increases Stake in Tianrun Industry
On March 12, Tianrun Industry announced that Yongying Ruixin, managed by Gao Nan, has increased its stake. As of March 10, Yongying Ruixin held approximately 12.25 million shares, which represents 1.22% of Tianrun’s total shares. Tianrun is the largest specialized manufacturer of engine crankshafts in China, producing a variety of automotive parts and components for internal combustion engines, railway equipment, and machine tool development.
As of the end of 2024, funds such as Shenwan Lingxin Fund are known to hold shares in Tianrun Industry. Southwest Securities Research notes that Tianrun is optimistic about opportunities arising from electrification and hybrid vehicles. The company is actively expanding globally, with plans to establish a factory in Thailand. According to the company’s disclosures, the factory is set to begin construction in the second half of 2024, with all necessary permits already secured. This facility will allow the company to relocate relevant production lines from China, thereby reducing equipment verification time.
Furthermore, Tianrun anticipates a growing demand for hybrid vehicles. From January to September 2024, sales of plug-in hybrid vehicles reached 3.328 million, marking a year-on-year increase of 84.2%. The company plans to adjust its internal product structure, shifting some light truck production lines to passenger vehicle crankshaft production. Currently, the production capacity for passenger vehicle crankshafts is fully utilized, and the company is enhancing capacity through key equipment and processes. The future performance of the company is expected to be strongly supported by the new energy vehicle and marine shaft business.
